The Magnum Ice Cream Company confirms inclusion in AEX index on Euronext AmsterdamAmsterdam 10 December 2025 | The Magnum Ice Cream Company (TMICC; AEX: “MICC”), the world’s largest ice cream company, today confirmed its inclusion in the AEX Index on Euronext Amsterdam as of its first day of trading on 8 December. The announcement follows Euronext’s quarterly index review, which is based on criteria, including free-float and market capitalisation.
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKDAllschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”.1 The analysis examined the efficacy and safety of aprocitentan (TRYVIO™/JERAYGO™) in patients with chronic kidney disease (CKD) and confirmed resistant hypertension – a population with very limited treatment options and high cardiovascular and renal risk.
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsSOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (
NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about December 11, 2025, subject to satisfaction of customary closing conditions.
Terns Announces Pricing of Upsized $650 Million Public OfferingFOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters’ option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions. All of the securities are being offered by Terns.
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded WarrantsSAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (
NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics.
Synopsys, Inc. Securities Fraud Class Action Result of Undisclosed Financial Problems and 35% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 30, 2025 to file lead plaintiff applications in securities class action lawsuits against Synopsys, Inc. (“Synopsys” or the “Company”) (NasdaqGS: SNPS), if they purchased or otherwise acquired the Company’s securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”) and/or purchased or otherwise acquired Synopsys common stock in exchange for their shares of Ansys, Inc. (“Ansys”) common stock in the acquisition of Ansys. These actions are pending in the United States District Court for the Northern District of California
Alexandria Real Estate Equities Securities Fraud Class Action Result of Financial Issues and Approximately 19% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK CITY and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (
NYSE: ARE), if they purchased or otherwise acquired the Company’s securities between January 27, 2025 to October 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
James Hardie Industries Securities Fraud Class Action Result of Sales Issues and +34% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 23, 2025 to file lead plaintiff applications in a securities class action lawsuit against James Hardie Industries plc (“James Hardie” or the “Company”) (
NYSE: JHX), if they purchased or otherwise acquired the Company’s shares between May 20, 2025, and August 18, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Sprouts Farmers Market, Inc. Securities Fraud Class Action Result of Undisclosed Financial Problems and 26% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Sprouts Farmers Market, Inc. (“Sprouts” or the “Company”) (NasdaqGS: SFM), if they purchased or otherwise acquired the Company’s securities between June 4, 2025 and October 29, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Arizona.
DeFi Technologies Inc. Securities Fraud Class Action Result of Undisclosed Financial Problems and 27% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against DeFi Technologies Inc. (“DeFi” or the “Company”) (NasdaqCM: DEFT), if they purchased or otherwise acquired the Company’s securities between May 12, 2025 and November 14, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
CarMax, Inc. Securities Fraud Class Action Result of Undisclosed Financial Problems and 20% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against CarMax, Inc. (
NYSE: KMX), if they purchased or otherwise acquired the Company’s securities between June 20, 2025 and November 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Maryland.
Stride, Inc. Securities Fraud Class Action Result of Customer Experience Issues and +54% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 12, 2026 to file lead plaintiff applications in a securities class action lawsuit against Stride, Inc. (“Stride” or the “Company”) (
NYSE: LRN), if they purchased or otherwise acquired the Company’s securities between October 22, 2024 and October 28, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Virginia.
Jayud Global Logistics Limited Securities Fraud Class Action Result of Massive Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 19, 2026 to file lead plaintiff applications in a securities class action lawsuit against Jayud Global Logistics Limited (“Jayud” or the “Company”) (NasdaqCM: JYD), if they purchased or otherwise acquired the Company’s securities between April 21, 2023 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Bitdeer Technologies Group Securities Fraud Class Action Result of Undisclosed Financial Problems and 14% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until February 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Bitdeer Technologies Group (“Bitdeer” or the "Company") (NasdaqCM: BTDR), if they purchased or otherwise acquired the Company’s securities between June 6, 2024 and November 10, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Six Flags Entertainment Corporation Securities Fraud Class Action Result of Undisclosed Financial Problems and 63% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSFNEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Six Flags Entertainment Corporation f/k/a CopperSteel HoldCo, Inc. (
NYSE: FUN), if they purchased or otherwise acquired the Company’s common stock pursuant or traceable to the company’s registration statement and prospectus issued in connection with the July 1, 2024 merger of legacy Six Flags Entertainment Corporation (“Legacy Six Flags”) with Cedar Fair, L.P. (“Cedar Fair”), and their subsidiaries and affiliates (the “Merger”). This action is pending in the United States District Court for the Northern District of Ohio.
Faraday Future Begins Production of the First FX Super One Pre-Production Vehicles at Its Hanford Facility, Nears Completion of the Bridge Closure for the Company’s Global Automotive Industry Bridge StrategyLOS ANGELES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (
NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that it has launched the start of assembly production of the FX Super One MPV pre-production vehicles at the Company’s Hanford, CA factory in anticipation of the first pre-production vehicle off the line ceremony planned for December 21. This milestone also marks the near completion of the Bridge Closure for the Company’s Bridge strategy, covering a closed loop of supply chain, testing, logistics, customs clearance and production. This further validates the feasibility and strategic value of the Bridge model, across tariff adaptation, ICTS compliance, cost management, and operational efficiency.
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsCAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common StockWALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $350.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about December 11, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,847,071 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Meshflow Acquisition Corp. Announces Pricing of $300 Million Initial Public OfferingCHICAGO, IL, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Meshflow Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market (“Nasdaq”) and begin trading on December 10, 2025, under the ticker symbol “MESHU”. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “MESH” and “MESHW,” respectively. The offering is expected to close on December 11, 2025, subject to customary closing conditions.
Vera Therapeutics Announces Pricing of Public Offering of Class A Common StockBRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share.
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 studies of its novel BTK inhibitor orelabrutinib were presented at the 67th Annual Meeting of the American Society of Hematology (ASH).
The Birth of a Creative PowerhouseThe TEAM at Fiesta Productions is Bringing Its Unique MAGIC to the 2026 Rose Parade® and Sharing a Behind the Scenes Preview of the WOW Moments it Will Be Delivering!
LRN INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Stride, Inc.NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- (BUSINESSWIRE)—The law firm of Kirby McInerney LLP reminds Stride, Inc. (“Stride” or the “Company”) (
NYSE: LRN) investors of the January 12, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Stride securities between October 22, 2025 through October 28, 2025 (“the Class Period”).
Rocket Lab Brings Forward Earth Observation Launch for KAIST, Liftoff Scheduled for TomorrowLONG BEACH, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced it is expediting a dedicated Electron mission for the Korea Advanced Institute of Science and Technology (KAIST) and is scheduling the launch from Launch Complex 1 in less than 24 hours’ time.
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) featuring Dr. Ralph DeFronzo, Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio. The interview highlights the growing body of preclinical and clinical findings supporting the use of icovamenib in patients with diabetes.
Strive Announces $500,000,000 SATA At-The-Market ProgramDALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced that it has entered into a sales agreement pursuant to which Strive may issue and sell shares of its Variable Rate Series A Perpetual Preferred Stock, $0.001 par value per share (the “SATA Stock”), having an aggregate offering price of up to $500,000,000 (the “ATM Program���).
ALT5 ALERT: Bragar Eagel & Squire, P.C. is Investigating ALT5 Sigma Corp on Behalf of ALT5 Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ALT5 (ALTS) To Contact Him Directly To Discuss Their Options
GAUZY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Gauzy Ltd and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Gauzy (GAUZ) To Contact Him Directly To Discuss Their Options
AVTR: Kirby McInerney LLP Advises Avantor, Inc. Investors of Class Action LawsuitNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Avantor, Inc. (“Avantor” or the “Company”) (
NYSE:AVTR) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
KLARNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Klarna Group plc on Behalf of Klarna Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Klarna (KLAR) To Contact Him Directly To Discuss Their Options
KOIL Energy to Present at Sidoti’s Year-End Virtual Investor Conference December 10-11HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, announced Erik Wiik, President and Chief Executive Officer of KOIL Energy, and Kurt Keller, Chief Financial Officer of KOIL Energy, will present and host one-on-one meetings with investors at Sidoti’s Year-End Virtual Investor Conference, taking place on December 10-11, 2025.
Tate Opens New Manufacturing Facility in Pocahontas, ArkansasPOCAHONTAS, Ark., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tate, a global leader in innovative, sustainable, and customer-driven infrastructure solutions for mission-critical data center environments, has officially launched its new state-of-the-art manufacturing facility in Pocahontas, Arkansas. The new site expands Tate’s North American production footprint and strengthens its ability to deliver advanced, high-performance data center solutions at scale.
Dorchester Minerals, L.P. Announces the Retirement of Mr. William Casey McManemin from the Board of Managers; Appointments of Mr. Robert C. Vaughn as Interim Chairman and Mr. Albert G. Nance III to the Board of ManagersDALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announces the retirement of Mr. William Casey McManemin from the Board of Managers of Dorchester Minerals Management GP LLC, the general partner of the Partnership’s general partner (the “Board”), effective December 31, 2025.
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual DiseaseSEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical DataTORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases is pleased to announce that it will host a live webinar on December 10, 2025 at 08:30 AM Eastern Time.
17 Education & Technology Group Inc. Announces Third Quarter 2025 Unaudited Financial ResultsBEIJING, Dec. 10, 2025 (GLOBE NEWSWIRE) -- 17 Education & Technology Group Inc. (
NASDAQ: YQ) (“17EdTech” or the “Company”), a leading education technology company in China, today announced its unaudited financial results for the third quarter of 2025.
AlphaVest Acquisition Corp and AMC Corporation Announce Closing of Business CombinationNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- AlphaVest Acquisition Corp (
NASDAQ: ATMV) (the “Company” or “AlphaVest”), a special purpose acquisition company, and AMC Corporation (“AMC”), a security and safety technology solutions company, today announced the completion of their previously announced business combination (“the Business Combination”).
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (
NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan.
Artisan Partners Asset Management Inc. Reports November 2025 Assets Under ManagementMILWAUKEE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Artisan Partners Asset Management Inc. (
NYSE: APAM) today reported that its preliminary assets under management ("AUM") as of November 30, 2025 totaled $180.8 billion. Artisan Funds and Artisan Global Funds accounted for $87.2 billion of total firm AUM, while separate accounts and other AUM1 accounted for $93.6 billion. During the fourth quarter of each year, certain Artisan Funds make their annual income and capital gains distributions. November month-end AUM includes the impact of approximately $800 million of Artisan Funds distributions that were not reinvested. Based on updated estimates, approximately $400 million of additional Artisan Funds distributions not reinvested are expected in December. Separately, the Firm had a $2.7 billion redemption in early December 2025 from a non-U.S. institutional client across three Growth team strategies, driven in part by local pension-market dynamics.
APA Corporation Declares Cash Dividend on Common SharesHOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The board of directors of APA Corporation (Nasdaq: APA) has declared a regular cash dividend on the company's common shares.
Apollo Commercial Real Estate Finance, Inc. Declares Quarterly Common Stock DividendNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Apollo Commercial Real Estate Finance, Inc. (the “Company”) (
NYSE:ARI) today announced the Board of Directors declared a dividend of $0.25 per share of common stock, which is payable on January 15, 2026 to common stockholders of record on December 31, 2025.
Enovix Announces December Investor EventsFREMONT, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX) (“Enovix”), a global high-performance battery company, today announced its participation in the following investor events:
Legence Announces Secondary Underwritten Public Offering of Class A Common StockSAN JOSE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today announced that selling stockholders affiliated with Blackstone Inc. (the “Selling Stockholders”) intend to offer and sell 7,000,000 shares of Legence’s Class A common stock, par value $0.01 (“Common Stock”) in a secondary underwritten public offering. In connection with the offering, the Selling Stockholders are expected to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of Common Stock on the same terms and conditions.
BillionToOne Reports Third Quarter 2025 ResultsMENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (
NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025.
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of three employees, the Compensation Committee of Sagimet’s Board of Directors approved inducement grants of 42,800 stock options in aggregate to purchase shares of the Company’s Series A common stock as determined based on the Black Scholes value on December 9, 2025, to be granted on December 9, 2025 to the three newly-hired employees.
Harvard Ave Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on December 15, 2025New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Ave Acquisition Corporation (the “Company”) (Nasdaq: HAVA), a blank check company, today announced that, commencing on December 15, 2025, holders of 14,500,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”), may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “HAVAU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “HAVA” and “HAVAR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, Continental Stock Transfer & Trust Company, in order to separate the holders’ Units into Class A ordinary shares and rights.
Lakeland Fire + Safety Reports Fiscal Third Quarter 2026 Financial ResultsQ3’26 Net Sales Increased 4% to $47.6 Million Led by 31% Increase in Fire Services Products, Representing 53% of Total Revenue
Capital Southwest Corporation Announces the Promotion of Grant Eason to Managing DirectorDALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses is pleased to announce the promotion of Grant Eason to Managing Director.
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. HospitalsBRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded WarrantsSOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (
NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Denali Therapeutics. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Frequency Electronics Announces Second Quarter Fiscal 2026 Financial Results Conference Call: Thursday, December 11, 2025, at 4:30 PM ETMITCHEL FIELD, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (
NASDAQ: FEIM), will hold a conference call to discuss results for the second quarter of its fiscal year 2026, ended October 31, 2025, on Thursday, December 11, 2025, at 4:30 PM Eastern Time.
Able View Announced Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencySHANGHAI, CHINA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Able View Global Inc. (Nasdaq: ABLV) (“Able View” or the “Company”), one of the largest comprehensive brand management partners of international beauty and personal care brands in China, today announced that on December 4, 2025, the Company received a notification letter from the Nasdaq Listing Qualifications Department (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement from October 22, 2025 through December 3, 2025. As set forth in the Nasdaq Listing Rules 5550(a)(2) (“Nasdaq Listing Rule”), it requires that the closing bid price for the Company’s ordinary shares listed on the Nasdaq be maintained at a minimum of USD$1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency.
National Association of REALTORS® Unveils Top 10 Homebuying Hot Spots for 2026NAR forecasts existing-home sales to jump by 14% and home prices to rise by 4% in 2026
CyberAI Group Announces the Filing of Three AI Cyber Defense PatentsPotentially Market-Disruptive Advanced Technology Addresses Ethical Use of AI
Silicon-Carbon Anode Project Granted $730,000, With Sunrise New Energy as a Key ParticipantDOVER, USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sunrise New Energy Co., Ltd. (“Sunrise”, the “Company”, “we” or “our”) (
NASDAQ: EPOW) today announced the successful mid-term evaluation of a Guizhou Provincial Science and Technology Major Project it is undertaking. The project, titled "Key Technologies and Engineering of Novel Silicon-Carbon Anode Materials for Lithium-ion Batteries," has been awarded $730,000, which is allocated to advance the next-stage development of the silicon-carbon anode project.
HII Hosts Keel Laying of Virginia-Class Attack Submarine Barb (SSN 804)NEWPORT NEWS, Va., Dec. 09, 2025 (GLOBE NEWSWIRE) -- HII’s (
NYSE: HII) Newport News Shipbuilding (NNS) division hosted the keel laying ceremony today for Virginia-class attack submarine Barb (SSN 804).
Darktrace Federal and Navitas Business Consulting Awarded Department of State Contract for AI-Powered Network Detection and ResponseDeployment underscores Darktrace Federal’s momentum amid continued investment, team expansion, and demand for AI-powered cyber resilience
Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global InsightsUS primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness.
Priority Income Fund Announces Preferred Stock Distributions for December 2025NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) announced today that the Fund’s Board of Directors has declared distributions on shares of the Fund’s 7.00% Series D Term Preferred Stock due 2029 (“Series D”), 6.000% Series J Term Preferred Stock due 2028 (“Series J”), 7.000% Series K Cumulative Preferred Stock (“Series K”), and 6.375% Series L Term Preferred Stock due 2029 (“Series L”).
White Lodging Names David Cirincione to Regional Director of OperationsMerrillville, Indiana, Dec. 09, 2025 (GLOBE NEWSWIRE) -- White Lodging, one of the hospitality industry’s leading hotel development, ownership, and management companies, is pleased to announce the promotion of David Cirincione to the role of Regional Director of Operations (RDO).
